Anti-HPV gel versus interferon α-2b gel as adjuvant therapy after LEEP for HSIL with HR-HPV infection on clinical outcomes, vaginal microecology, and biomarkers of proliferation and immunity
Frontiers in Oncology · 25.03.2026 · 16
DOI: 10.3389/fonc.2026.1784137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 25.03.2026. Verfasst von Xu Long und 5 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Women's and Children's Hospital of the University of Electronic Science and Technology of China, Gynecology Department of Chengdu Women's …. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To evaluate and compare the efficacy, impact on vaginal microbiota, changes in inflammatory/immune/proliferation biomarkers, and safety profile of Anti-HPV gel versus Interferon α-2b gel as adjuvant therapies after LEEP in patients with HSIL and HR-HPV infection.
Methods
This retrospective cohort study included 207 eligible patients diagnosed with HSIL and HR-HPV infection who underwent initial LEEP between January 2023 and January 2025. Patients were divided into a control group (n=102, Interferon α-2b gel) and an observation group (n=105, Anti-HPV gel), both receiving two standardized treatment courses post-operatively. Outcome measures included total clinical effective rate, vaginal microecological recovery (pH, Nugent score), serum inflammatory cytokines (IL-17, TNF-α, IFN-γ, TGF-β), immunoglobulins (IgA, IgG, IgM), cell proliferation markers (serum Survivin, cervical tissue Ki-67), adverse events, and 6-month HR-HPV recurrence rate. An exploratory model was constructed using post-treatment indicators to predict recurrence.
Results
Compared with the control group, the observation group showed superior outcomes across multiple domains: a higher total clinical effective rate (87.62% vs. 75.49%, P = 0.024); better restoration of vaginal microecology with lower post-treatment pH (4.29 ± 0.37 vs. 4.78 ± 0.42, P<0.001) and Nugent score (2.96 ± 1.15 vs. 4.52 ± 1.37, P<0.001); greater reductions in serum inflammatory markers (IL-17, TNF-α, IFN-γ, TGF-β, all P<0.001); greater increases in immunoglobulins (IgA, IgG, IgM, all P<0.001); more pronounced decreases in cell proliferation markers (serum Survivin and tissue Ki-67, both P<0.001); a lower 6-month HR-HPV recurrence rate (6.67% vs. 16.67%, P = 0.024) with comparable overall adverse event incidence (10.48% vs. 13.73%, P = 0.473). The exploratory predictive model based on post-treatment indicators demonstrated good discrimination for recurrence (AUC = 0.812, 95% CI: 0.747–0.878).
Conclusion
In conclusion, as a postoperative adjuvant, Anti-HPV gel demonstrated superior clinical and biomarker outcomes compared to Interferon α-2b gel, with a favorable safety profile and lower short-term recurrence risk, suggesting its promising clinical value pending prospective confirmation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Affiliated Women's and Children's Hospital of the University of Electronic Science and Technology of China, Gynecology Department of Chengdu Women's and Children's Central Hospital, Chengdu, Sichuan, China.
- Clinical Laboratory Department, Women's and Children's Hospital Affiliated to University of Electronic Science and Technology of China, Chengdu Women's and Children's Central Hospital, Chengdu, Sichuan, China.
- Zhongyi Hospital of Traditional Chinese Medicine, Department of Gynecology, Chengdu, Sichuan, China.
- Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Department of Gynecology, Chengdu, Sichuan, China.
- Affiliated Women's and Children's Hospital of the School of Medicine, University of Electronic Science and Technology of China, Chengdu Women's and Children's Central Hospital Traditional Chinese Medicine Gynecology, Ch…
Zitieren
APA
Long, X., Luo, M., Yang, C., Yan, F., Pu, H., & Li, X. (2026). Anti-HPV gel versus interferon α-2b gel as adjuvant therapy after LEEP for HSIL with HR-HPV infection on clinical outcomes, vaginal microecology, and biomarkers of proliferation and immunity. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1784137
Vancouver
Long X, Luo M, Yang C, Yan F, Pu H, Li X. Anti-HPV gel versus interferon α-2b gel as adjuvant therapy after LEEP for HSIL with HR-HPV infection on clinical outcomes, vaginal microecology, and biomarkers of proliferation and immunity. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1784137
BibTeX
@article{Long2026,
author = {Long, Xu and Luo, Mengjun and Yang, Chunrong and Yan, Fengying and Pu, Hongou and Li, Xiaohong},
title = {Anti-HPV gel versus interferon α-2b gel as adjuvant therapy after LEEP for HSIL with HR-HPV infection on clinical outcomes, vaginal microecology, and biomarkers of proliferation and immunity},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1784137}
}
EUVIMED